Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Dec 16, 2024
- Pharmaceuticals
- R&D
Galderma’s Announcement Regarding Nemolizumab (CHMP Positive Opinion for the Treatment of Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis)
TOKYO, December 16, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma issued a press release on December 13 that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended to approve nemolizumab for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis. Nemolizumab was created by Chugai, and its clinical development outside Japan is being conducted by Galderma.
Please refer to the link below for details of the Galderma’s press release:
CHMP recommends approval of Galderma’s nemolizumab for moderate-to-severe atopic dermatitis and prurigo nodularis in the European Unionhttps://www.galderma.com/news/chmp-recommends-approval-galdermas-nemolizumab-moderate-severe-atopic-dermatitis-and-prurigo
Trademarks used or mentioned in this release are protected by laws.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp